CODX vs. DXR, SURG, BDMD, POCI, SPAI, CLGN, FEMY, PYPD, COCH, and NMTC
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include Daxor (DXR), SurgePays (SURG), Baird Medical Investment (BDMD), Precision Optics (POCI), Safe Pro Group Inc. Common Stock (SPAI), CollPlant Biotechnologies (CLGN), Femasys (FEMY), PolyPid (PYPD), Envoy Medical (COCH), and NeuroOne Medical Technologies (NMTC). These companies are all part of the "medical equipment" industry.
Co-Diagnostics vs.
Daxor (NASDAQ:DXR) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.
Daxor has higher earnings, but lower revenue than Co-Diagnostics.
Daxor has a net margin of 0.00% compared to Co-Diagnostics' net margin of -563.93%. Daxor's return on equity of 0.00% beat Co-Diagnostics' return on equity.
1.3% of Daxor shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 59.0% of Daxor shares are owned by company insiders. Comparatively, 6.1% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Daxor currently has a consensus price target of $25.00, indicating a potential upside of 210.56%. Co-Diagnostics has a consensus price target of $1.00, indicating a potential upside of 171.00%. Given Daxor's stronger consensus rating and higher probable upside, equities research analysts clearly believe Daxor is more favorable than Co-Diagnostics.
Daxor has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.
In the previous week, Daxor had 6 more articles in the media than Co-Diagnostics. MarketBeat recorded 7 mentions for Daxor and 1 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 1.89 beat Daxor's score of 0.80 indicating that Co-Diagnostics is being referred to more favorably in the news media.
Co-Diagnostics received 271 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 62.76% of users gave Co-Diagnostics an outperform vote.
Summary
Daxor beats Co-Diagnostics on 10 of the 15 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CODX) was last updated on 4/12/2025 by MarketBeat.com Staff
Buy CODX Stock Free CODX Stock Alerts